Ferring Pharmaceuticals and WOOM today announced a collaboration, which
aims to improve and shorten the fertility journeys of the one in six
couples who have difficulty conceiving.1
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190618005741/en/
Ferring Collaboration with Digital Health Innovators WOOM Aims to Help More People Build Families Faster
The WOOM ovulation and fertility app, currently available in Spanish –
with registered users across Spain, Mexico, Colombia, Chile, Argentina
and Peru – is able to analyse a woman’s menstrual cycle, lifestyle
factors and biometrics to help couples better understand their bodies to
either help conceive naturally or go and see a specialist as soon as
possible. The app was developed in partnership with medical
professionals.
As part of the partnership with Ferring, a test group of 500 WOOM users
from across Spain and/or Latin America will be assessed via a bespoke
Fertility Programme. The programme creates a personalised journey that
will help couples know faster if they have any fertility challenges and
connect potential parents with local fertility services, helping unlock
the door to earlier fertility treatment intervention.
‘With over 50 years of heritage in reproductive medicine, we have the
expertise to interpret trends captured through the WOOM app, and to use
those insights to enable more people to navigate their fertility
journeys quickly and easily,’ said Klaus Dugi, Chief Medical
Officer, Ferring Pharmaceuticals. ‘On a macro level, it’s our hope
that this collaboration will positively and measurably impact the future
of fertility access and treatment, so that more people worldwide can
build a family.’
‘We created WOOM in response to our personal experiences of becoming
pregnant and by understanding the large need of having relevant
information that you can trust and that is applied to you,’ said
Laurence Fontinoy Co-founder and CEO of WOOM, ‘We already have over
600,000 users across Spanish speaking countries and, by collaborating
with Ferring, a renowned leader in the fertility space, we hope to
expand our reach to help more people achieve their dream of becoming
parents sooner.’
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty
biopharmaceutical group committed to helping people around the world
build families and live better lives. Headquartered in Saint-Prex,
Switzerland, Ferring is a leader in reproductive medicine and women’s
health, and in specialty areas within gastroenterology and urology.
Ferring has been developing treatments for mothers and babies for over
50 years and has a portfolio covering treatments from conception to
birth. Founded in 1950, privately-owned Ferring now employs
approximately 6,500 people worldwide, has its own operating subsidiaries
in nearly 60 countries and markets its products in 110 countries.
Learn more at www.ferring.com,
or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
About WOOM
WOOM is a women’s technology company that through data provided by women
such as menstrual cycle, age and lifestyle, helps to predict the chances
of pregnancy and thus increase their chances of conceiving. WOOM also
focuses on women’s health and helps all women by providing them with
personalised information for each of them. This FemTech company has a
community where all women create groups and talk freely about their
experiences, helping and giving advice to all those who need it. With
600,000 records and 900,000 downloads, it has helped more than 128,000
women become pregnant within 3 years.
Learn more at https://woomfertility.com/,
or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
References:
1. Thoma ME et al. Prevalence of infertility in the United
States as estimated by the current duration approach and a traditional
constructed approach. Fertil Steril. 2013
Apr;99(5):1324-1331.e1.
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005741/en/